{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=6&q=BTK+inhibitor", "query": { "q": "BTK inhibitor", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 311, "total_pages": 32, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=7&q=BTK+inhibitor&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=5&q=BTK+inhibitor&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T13:23:36.173Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02180724", "title": "An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Waldenström Macroglobulinemia (WM)" ], "interventions": [ { "name": "Acalabrutinib (ACP-196)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acerta Pharma BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2014-09-11", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-23T13:23:36.173Z", "location_count": 10, "location_summary": "Santa Barbara, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more", "locations": [ { "city": "Santa Barbara", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02180724" }, { "nct_id": "NCT03710772", "title": "Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 51, "start_date": "2019-05-01", "completion_date": "2027-03-22", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-10-23T13:23:36.173Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03710772" }, { "nct_id": "NCT04115631", "title": "A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Lymphoma", "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Bendamustine Hydrochloride", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 360, "start_date": "2019-12-13", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-23T13:23:36.173Z", "location_count": 504, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 358 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04115631" }, { "nct_id": "NCT02180711", "title": "Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Hodgkin Lymphoma" ], "interventions": [ { "name": "acalabrutinib", "type": "DRUG" }, { "name": "rituximab (IV)", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acerta Pharma BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 113, "start_date": "2014-12-29", "completion_date": "2028-12-11", "has_results": true, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-23T13:23:36.173Z", "location_count": 23, "location_summary": "Tucson, Arizona • Downey, California • Duarte, California + 18 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Downey", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02180711" }, { "nct_id": "NCT04209621", "title": "Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Lymphocytic Leukemia (SLL)", "Chronic Lymphocytic Leukemia (CLL)" ], "interventions": [ { "name": "Duvelisib", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2020-07-31", "completion_date": "2021-01-22", "has_results": true, "last_update_posted_date": "2022-03-09", "last_synced_at": "2026-10-23T13:23:36.173Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04209621" }, { "nct_id": "NCT03926611", "title": "This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Spontaneous Urticaria" ], "interventions": [ { "name": "LOU064 Arm 1", "type": "DRUG" }, { "name": "LOU064 Arm 2", "type": "DRUG" }, { "name": "LOU064 Arm 3", "type": "DRUG" }, { "name": "LOU064 Arm 4", "type": "DRUG" }, { "name": "LOU064 Arm 5", "type": "DRUG" }, { "name": "LOU064 Arm 6", "type": "DRUG" }, { "name": "Placebo arm", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 311, "start_date": "2019-06-06", "completion_date": "2021-04-15", "has_results": true, "last_update_posted_date": "2022-04-29", "last_synced_at": "2026-10-23T13:23:36.173Z", "location_count": 11, "location_summary": "Litchfield Park, Arizona • Little Rock, Arkansas • Mission Viejo, California + 8 more", "locations": [ { "city": "Litchfield Park", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Mission Viejo", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Walnut Creek", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03926611" }, { "nct_id": "NCT04484012", "title": "Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Mantle Cell Lymphoma", "Refractory Mantle Cell Lymphoma" ], "interventions": [ { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 36, "start_date": "2020-12-31", "completion_date": "2027-02-23", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-23T13:23:36.173Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04484012" }, { "nct_id": "NCT07882173", "title": "Epcoritamab as Consolidative Therapy for Waldenstr(SqrRoot)(Delta)m Macroglobulinemia (WM) Treated With a Bruton Tyrosine Kinase Inhibitor (BTKi)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "epcoritamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 24, "start_date": "2026-10-28", "completion_date": "2033-11-01", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-23T13:23:36.173Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07882173" }, { "nct_id": "NCT07221500", "title": "A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia (CLL)", "Small Lymphocytic Lymphoma (SLL)" ], "interventions": [ { "name": "NX-5948", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nurix Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2025-10-15", "completion_date": "2030-10", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-10-23T13:23:36.173Z", "location_count": 27, "location_summary": "Phoenix, Arizona • Duarte, California • Los Angeles, California + 23 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07221500" }, { "nct_id": "NCT02532257", "title": "Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ann Arbor Stage II Follicular Lymphoma", "Ann Arbor Stage II Marginal Zone Lymphoma", "Ann Arbor Stage III Follicular Lymphoma", "Ann Arbor Stage III Marginal Zone Lymphoma", "Ann Arbor Stage IV Follicular Lymphoma", "Ann Arbor Stage IV Marginal Zone Lymphoma", "CD20 Positive", "Grade 1 Follicular Lymphoma", "Grade 2 Follicular Lymphoma", "Grade 3a Follicular Lymphoma" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2016-04-11", "completion_date": "2023-08-15", "has_results": true, "last_update_posted_date": "2024-09-24", "last_synced_at": "2026-10-23T13:23:36.173Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02532257" } ] }